Product Information
Phase Detail
Zebron ZB-624<em>PLUS</em> GC Columns
Zebron ZB-624PLUS GC column offers increased sensitivity for high boiling solvents

Zebron ZB-624PLUS GC Columns

The Next Generation of GC Inertness

Zebron ZB-624PLUS is the optimal choice for the analysis of volatile compounds for Environmental, Pharmaceutical, Food, Cannabis, and Specialty Chemicals. The superior “Plus” deactivation process enhances peak shape, improves signal-to-noise levels and increases sensitivity for qualitative and quantitative analysis of active compounds. Upgrade your existing 624 phase to Zebron ZB-624PLUS GC columns and get all the analytical benefits of proven inertness.

  • Enhanced Peak Shape with Superior Deactivation
  • Increased Sensitivity for High Boiling Solvents
  • Extremely Low Bleed for GC-MS
  • High Temperature Stability (300/320 ˚C)

Upgrade to Zebron from these similar* phases:

Agilent® Restek®
CP-Select 624 CB
DB-624UI Ultra Inert
Rxi®-624Sil MS

zb624plus


Temperature Limits
-20 to 300/320
Phase
ZB-624plus
Recommended Use
Enhanced peak shape with superior deactivation and increased sensitivity for high boiling solvent, extremely low bleed for GC-MS with high temperature stability (300/320°C)

The Next Generation of GC Inertness




Recommended For:
Cannabis
Terpenes
Residual Solvents
Volatile Amines
EPA Method 8260
EPA Method 524
EPA Method 624
Food
Flavors and Fragrances
Solvent Purity
Alcohols

Meet your Zebron ZB-624PLUS GC Column


What makes the PLUS in ZB-624PLUS?

Low Bleed Engineered Self Cross-linking™ (ESC) provides high thermal stability with maximum column temperatures up to 300/320 ˚C
Enhance Inertness Proprietary superior deactivation gives great peak shape for troublesome compounds.
High Selectivity A G43 phase that’s highly selective for polar, non-polar, low and high boiling solvents.
Column-to-Column
Reproducibility
Excellent column-to-column reproducibility well suited for validated methods.
Temperature Limits Push the temperature limits of traditional 624 and elute/bake high boiling analytes at 300/320 °C.

Low Bleed = Better Signal-to-Noise Ratio = Lower Detection Limits

The low bleed character of ZB-624PLUS™ columns is the result of advances in cross-linking manufacturing processes that we established for these columns.

With ZB-624PLUS™, your GC column undergoes proprietary cross-linking process to get extensive Engineered Self Cross-linkage (ESC™).



Improved Peak Shape of Volatile Amines

Volatile amines are challenging analytes for GC analysis. They can adsorb to even the smallest imperfections in fused silica. ZB-624PLUS™ undergoes a superior deactivation process which minimizes active compound adsorption leading to gains in Peak response and shape

Comparison of Volatile Amines on Various 624 Columns

Comparative separations may not be representative of all applications.
GC Conditions for all separations:

Column:
Zebron ZB-624PLUS
Dimension:
30 meter x 0.32 mm x 1.8 µm
Part No.:
7HM-G040-31 (ZB-624PLUS)
Injection:
Split 20:1 1 µL @ 140 °C,
Recommended Liner:
Zebron PLUS Liner Straight Z-Liner™
Liner Part No.:
AG2-0A03-05 (for Agilent & Thermo Scientific® systems)
Carrier Gas:
Helium @ 1.8 mL/min (constant flow)
Oven Program:
50 °C for 1 min, to 200 °C @ 20 °C/min for 5 min
Detector:
FID @ 250 °C
Sample:
1. Isopropylamine
2. Diethylamine
3. Triethylamine

Exceeding USP <467> System Suitability

USP <USP> method requires resolution of 1.5 for critical pairs. Zebron™ ZB-624PLUS™ took the challenge and succeeded.

Column:
Zebron ZB-624PLUS
Dimension:
30 meter x 0.32 mm x 1.80 µm
Part No.:
7HM-G040-31
Injection:
Split 5:1 1 µL @ 140 °C,
Recommended Liner:
Zebron PLUS Straight Z-Liner™
Liner Part No.:
AG2-0A03-05  (for Agilent & Thermo Scientific® systems)
Carrier Gas:
Helium @ 2.2 mL/min (constant flow)
Oven Program:
40 °C for 20 min to 240 °C @ 10 °C/min
Detector:
FID @ 250 °C

“YES!”

The number of plates is better for later eluting (higher boiling) solvents. We can use this column directly for routine analysis, with the bonus that higher temperatures can be used! – Dr. Marek Mahut, Novartis, Switzerland

The opinions stated herein are solely those of the speaker and not necessarily those of any company or organization.